In the included patients ( n = 40 otelixizumab , n = 40 placebo ) , - cell function was assessed as area under the curve ( AUC ) C-peptide release during a hyperglycemic glucose clamp at baseline ( median duration of insulin treatment : 6 days ) and every 6 months until 18 months after randomization .